英国达芦那韦治疗中HIV-1耐药突变的出现:PI初治与经治患者比较
基于英国协作HIV队列中6918例接受达芦那韦者,386例有暴露前后耐药检测。总体2.8%出现新发达芦那韦耐药突变;基线耐药突变在PI初治者中占1.0%、经治者中占13.8%,新发突变分别占2.0%和3.7%。PI初治组中 codon 77 被正向选择。
要点
- 达芦那韦新发耐药突变总体罕见(2.8%),但PI经治者新发比例高于初治者。
- PI经治者基线耐药突变流行率(13.8%)明显高于初治者(1.0%)。
- codon 77 在PI初治达芦那韦病例中被正向选择,是否为新耐药位点待研究。
核心结论
- 达芦那韦治疗中新发耐药突变虽罕见,但在PI经治患者中可能比PI初治患者更常见。
- codon 77 在PI初治达芦那韦病例中被正向选择,需进一步研究其是否参与达芦那韦敏感性。
研究设计与样本
- 研究基于英国协作HIV队列(UK Collaborative HIV Cohort Study)中接受达芦那韦者,比较暴露前后蛋白酶基因型。
- 6918例接受达芦那韦者中,386例有暴露前后耐药检测,分析按PI用药史分层。
- 采用选择分析比较达芦那韦受者与匹配的PI初治对照者中B亚型蛋白酶进化。
主要发现
- 386例有暴露前后耐药检测者中,2.8%(11/386)出现新发达芦那韦耐药突变。
- 基线耐药突变在PI初治者中为1.0%(2/198),在PI经治者中为13.8%(26/188)。
- 新发耐药突变在PI初治组占2.0%(4个突变),在PI经治组占3.7%(12个突变)。
- codon 77 在PI初治达芦那韦病例中被正向选择,而对照组中未出现。
临床怎么用
- 对PI经治患者使用达芦那韦时应关注基线耐药突变及治疗中新发耐药风险。
- PI初治患者达芦那韦耐药突变风险较低,但仍需结合病毒学应答监测。
局限性
- 仅386例有暴露前后耐药检测,样本量有限。
- 耐药突变通过临床常规检测识别,可能低估罕见突变。
- codon 77 的临床意义尚未明确,需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Darunavir is considered to have a high genetic barrier to resistance. Most darunavir-associated drug resistance mutations (DRMs) have been identified through correlation of baseline genotype with virological response in clinical trials. However, there is little information on DRMs that are directly selected by darunavir in clinical settings. OBJECTIVES: We examined darunavir DRMs emerging in clinical practice in the UK. PATIENTS AND METHODS: Baseline and post-exposure protease genotypes were compared for individuals in the UK Collaborative HIV Cohort Study who had received darunavir; analyses were stratified for PI history. A selection analysis was used to compare the evolution of subtype B proteases in darunavir recipients and matched PI-naive controls. RESULTS: Of 6918 people who had received darunavir, 386 had resistance tests pre- and post-exposure. Overall, 2.8% (11/386) of these participants developed emergent darunavir DRMs. The prevalence of baseline DRMs was 1.0% (2/198) among PI-naive participants and 13.8% (26/188) among PI-experienced participants. Emergent DRMs developed in 2.0% of the PI-naive group (4 mutations) and 3.7% of the PI-experienced group (12 mutations). Codon 77 was positively selected in the PI-naive darunavir cases, but not in the control group. CONCLUSIONS: Our findings suggest that although emergent darunavir resistance is rare, it may be more common among PI-experienced patients than those who are PI-naive. Further investigation is required to explore whether codon 77 is a novel site involved in darunavir susceptibility.
引用
- El Bouzidi K, White E, Mbisa JL, et al. HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK. J Antimicrob Chemother. 2016. PMID: 27856703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。